Cargando…

Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of...

Descripción completa

Detalles Bibliográficos
Autor principal: Pardridge, William M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697739/
https://www.ncbi.nlm.nih.gov/pubmed/33207605
http://dx.doi.org/10.3390/ph13110394

Ejemplares similares